Loading...
XNAS
CMPS
Market cap1.31bUSD
Jul 09, Last price  
13.60USD
1D
-2.61%
1Q
145.93%
IPO
-52.83%
Name

Compass Pathways PLC

Chart & Performance

D1W1MN
XNAS:CMPS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.08%
Rev. gr., 5y
%
Revenues
0k
Net income
-288m
L+85.57%
-13,219,000-19,612,000-60,803,335-71,742,000-91,505,000-118,464,000-155,122,000-287,862,000
CFO
-157m
L+31.93%
-9,801,000-17,813,000-41,380,000-67,745,000-105,451,000-97,376,000-119,186,000-157,240,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
URL
https://compasspathways.com/
IPO date
Sep 18, 2020
Employees
181
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT